Plus TherapeuticsPSTV +7.71%30 FCF Yield % is -74.08 as of Jun. 25, 2026. GuruFocus rates PSTV with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, Plus Therapeutics ranks worse than 88.01% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Plus Therapeutics FCF Yield % Related Terms
Plus Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Plus Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Plus Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (PSTV) has a FCF Yield % of -74.08 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Plus Therapeutics and its competitors. According to the industry distribution chart, Plus Therapeutics ranks #1248 out of 1418 companies in the Biotechnology industry, placing it in the top 88%.
Is Plus Therapeutics' FCF Yield % too high?
Plus Therapeutics' current FCF Yield % is -74.08. Based on the distribution chart, Plus Therapeutics ranks #1248 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Plus Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Plus Therapeutics' FCF Yield % compare to GRCE and NNVC?
According to the Biotechnology industry distribution chart, Plus Therapeutics ranks #1248 out of 1418 companies for FCF Yield %. This places Plus Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Plus Therapeutics and its competitors. Plus Therapeutics's current FCF Yield % is -74.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plus Therapeutics stock overvalued right now?
Plus Therapeutics (PSTV) has a current FCF Yield % of -74.08. The current FCF Yield % is -74.08. Plus Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Plus Therapeutics (PSTV), the current FCF Yield % is -74.08 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
30GF Score
Get the complete analysis for PSTV
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PSTV has been successfully added to your 
